Metaphors in Nanomedicine: The Case of Targeted Drug Delivery by Bensaude Vincent, Bernadette & Loeve, Sacha
Metaphors in Nanomedicine: The Case of Targeted
Drug Delivery
Bernadette Bensaude Vincent, Sacha Loeve
To cite this version:
Bernadette Bensaude Vincent, Sacha Loeve. Metaphors in Nanomedicine: The Case
of Targeted Drug Delivery. NanoEthics, Springer Verlag, 2014, 8 (1), pp.1 - 17.
<http://link.springer.com/article/10.1007
HAL Id: halshs-01076477
https://halshs.archives-ouvertes.fr/halshs-01076477
Submitted on 22 Oct 2014
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Authors-generated preprint | NanoEthics, 2014, vol. 8, n°1, pp. 1-17 | DOI 10.1007/s11569-013-0183-5 
http://link.springer.com/article/10.1007%2Fs11569-013-0183-5 
 1 
 
 
 
Metaphors in Nanomedicine: 
The Case of Targeted Drug Delivery 
 
 
 
Bernadette Bensaude Vincent, Cetcopra, Université Paris 1 & IUF 
bensaudevincent@gmail.com 
 
Sacha Loeve, Cetcopra, Université Paris 1 
sacha.loeve@univ-paris1.fr 
 
ABSTRACT  
The promises of nanotechnology have been framed by a variety of metaphors, that not 
only channel the attention of the public, orient the questions asked by researchers, and convey 
epistemic choices closely linked to ethical preferences. In particular, the image of the 
‘therapeutic missile’ commonly used to present targeted drug delivery devices emphasizes 
precision, control, surveillance and efficiency. Such values are highly praised in the current 
context of crisis of pharmaceutical innovation where military metaphors foster a general 
mobilization of resources from multiple fields of cutting-edge research. The missile metaphor, 
reminiscent of Paul Ehrlich’s ‘magic bullet’, has framed the problem in simple terms: how to 
deliver the right dose in the right place at the right moment? Chemists, physicists and 
engineers who design multi-functional devices operating in vitro can think in such terms, as 
long as the devices are not actually operating through the messy environment of the body. A 
close look at what has been done and what remains to be done suggests that the metaphor of 
the “therapeutic missile” is neither sufficient, nor even necessary. Recent developments in 
nanomedicine suggest that therapeutic efficacy cannot be obtained without negotiating with 
the biological milieu and taking advantage of what it affords. An ‘oïkological’ approach 
seems more appropriate, more heuristic and more promising than the popular missile. It is 
based on the view of organism as an oikos that has to be carefully managed. The dispositions 
of nanocapsules have to be coupled with the affordances of the environment. As it requires 
dealing with nanoparticles as relational entities (defined by their potential for interactions) 
rather than as stable substances (defined by intrinsic properties) this metaphor eventually 
might well change research priorities in nanotechnology in general. 
 
 
 
KEY WORDS: nanomedicine; pharmacology; nanorobot; magic bullet; dispositions; 
affordances; efficiency; efficacy.
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Metaphors in Nanomedicine: 
The Case of Targeted Drug Delivery 
 
 
 
 
 
Introduction 
 
The use of nanoparticles for delivering drugs on a specific site is one of the most attractive 
promises of nanotechnology today. Targeted drug delivery systems are nanostructures tailored 
to deliver pharmaco-active molecules just where it is needed (Manish and Vimukta, 2011, p. 
135). The major advantage of drug vectorization is that it reduces the systemic toxicity of the 
medicine, thus minimizing side effects while improving its efficacy (Drews, 2000). In 
addition, this technique allows treating body parts that were once out of reach from most 
medicines (e.g.: the brain). Finally, the innovation is also sought for ‘rescuing’ or 
‘repurposing’ drugs that were shelved for being too toxic.  
Targeted drug delivery systems are flagship products of nanotechnology. Being less 
controversial than military applications of nanotechnology, such “nano-weapons” encourage 
public acceptance of nanotechnology. Reminiscent of the popular image of the ‘magic bullet’, 
current research projects in nanotechnology for drug delivery are pervaded by a host of 
warfare metaphors such as ‘therapeutic missiles’, ‘nano bullets’, ‘nano-weapons’, ‘smart 
bombs’, ‘stealth kill’, and ‘targeted strike’ without ‘collateral damages’ (Gabizon, 2001; 
Bhattacharya, 2003; Harney 2004; Patel 2007; Perez, 2008; Kain, 2008; Choi, 2009; 
Henderson 2009; Singer 2009; Rai et al. 2012; Rossi 2012). Such metaphors used in popular 
journals and scientific publications have shaped the conceptual structure of the research field.  
To be sure, this is not specific to nanomedicine. Warfare metaphors have pervaded 
medicine and healthcare for a very long time (Montgomery, 1991; 1996; Annas, 1995; 
Arrigo, 1999). Their use has been reinforced by the ‘War on Cancer’, launched by Richard 
Nixon in the 1970s. Focusing on the role of metaphors in nanomedicine, this paper pursues 
previous reflections on the uses and abuses of such metaphors (Nordmann, 2004; Nerlich, 
2012). However, it goes further in claiming that the values underlying the dominant 
metaphoric framework are not sustainable enough to design nano-artefacts operating in a 
complex biological milieu.  
Following a brief presentation of metaphors as conceptual tools, we contextualize the use 
of the missile metaphor against the background of the current pharmaceutical innovation 
crisis in relation to the history of pharmaceutical doctrines. Taking a closer look at the devices 
that have been designed over the past decades and at current research trends in this field we 
then argue that the missile or bullet metaphor provides a simplistic view of the complex 
technological systems required to achieve therapeutic efficacy. The military metaphor may 
suffice for chemists, physicists and engineers who design multi-functional devices operating 
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in vitro, as long as they do not operate in the complex and messy environment of a diseased 
body. But actions and reactions of biological milieu must be integrated into the operational 
scheme of therapeutic devices. To go beyond efficiency and achieve therapeutic efficacy in 
vivo, nanodevices have to be designed not only as destructive weapons but as protective shells 
as well as secret agents conducting negotiations; the biological environment should be 
conceived as a dense milieu populated with multiple and heterogeneous actors rather than as 
an abstract space traversed by a moving body. Finally, we argue that the use of alternative 
‘oïkological’ metaphors encapsulating not just the dispositions of the nano-object but also the 
affordances of the milieu may be useful to improve the technique. This requires dealing with 
nanoparticles as entities defined by their relations rather than as stable physical or chemical 
substances thereby calling for a redefinition of research priorities. 
This claim is based on a number of research papers dealing with targeted drug delivery 
both in standard scientific journals and pharmaceutical research journals. Our review of 
literature has been guided and completed by oral interviews and extensive discussions with 
three scientists working specifically research field.1  
 
The Performances of Metaphors 
 
It is less a matter of questionning the performances of the therapeutic applications of 
nanotechnology than addressing the relevance of metaphors used in the design of nanovectors. 
However, it is not a mere clarification of words, disregarding concepts, material practices and 
ethical choices. Richard Rorty claims: ‘It is pictures rather than propositions, metaphors rather 
than statements, which determine most of our philosophical convictions’ (Rorty, 1979, p. 
12).2 Metaphors defined as acts of ‘understanding and experiencing one kind of thing in terms 
of another’, are ordinary cognitive phenomena rather than mere stylistic devices (Lakoff and 
Johnson, 1980, p. 5). As the source domain shapes the ‘target domain’, metaphors allow 
grasping and shaping hitherto-unstructured or not-easily-accessible realities. Metaphors 
matter. They are powerful ‘catalysts’ in the dynamics of knowledge; they provide insights and 
generate new meanings and knowledge (Maassen and Weingart, 2000).  
Metaphors are also vehicles for the transmission of meaning and values. Like viruses, 
they contaminate and colonise our minds regardless of well-established boundaries such as 
science versus society. George Lakoff and Mark Johnson emphasize that war metaphors are 
ubiquitous in the practices of arguing (we ‘defend’ or ‘attack’, ‘gain’ or ‘lose’, ‘demolish’). 
They argue that not just our words, but our common world would be quite different had 
‘dance’ been, for instance, the source domain of metaphors (1980, pp. 4-5). Metaphors do 
literally change the world. They belong to the realm of what John L. Austin called 
‘performative utterances’ (Austin, 1962). They are ‘performative’ and not ‘constative’. More 
than describing reality, they inform and transform it.  
Scientific language is not deprived of performativity. Metaphors proliferate in the 
language of science for the purpose of communicating science to lay audiences, and they also 
circulate inside scientific communities. Evelyn Fox Keller’s works outline the heuristic power 
of metaphors in biology (Fox Keller, 1992; 1995; 2002). ‘Different metaphors of mind, 
nature, and the relation between them, reflect different psychological stances of observer to 
observed; these, in turn, give rise to different cognitive perspectives—to different aims, 
                                                 
1
 Interviews with Patrick Couvreur (Institut Galien Université Paris-Sud), Florence Gazeau (Laboratoire matière 
et systèmes complexes, Université Paris Diderot) and Ania Servant (Nanomedicine Laboratory, University 
College London School of Pharmacy). 
2
 In Rorty’s pragmatic philosophy, language is ‘image-schematic’ but it is not a representational ‘mirror of 
nature’: it is ‘formative’, i.e.: giving instructions to others about to give form to something, and per-formative, 
i.e.: being ‘instructive’ in that sense.   
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questions, and even to different methodological and explanatory preferences’ (1992, p. 30). 
She insists that ‘metaphors do far more than affect our perception of the world. They draw the 
attention of researchers, guide their activities and material manipulations’ (2002, p. 290). In 
technology, metaphors can even be turned into operational analogies that make things work 
and help superseding obstacles.  
What is exactly the descriptive power of the therapeutic missile metaphor (its adequacy) 
in nanomedicine? What about its prescriptive potential: does it shape research practices in this 
field? This metaphor suggests that new therapeutics can be framed along the model of 
ballistics. The objective is to carry and deliver the drug onto a target in order to optimize its 
‘launching window’. Precision guidance, efficiency without ‘collateral damages’, … the 
advantages of nanovectors are listed in terms similar to those used to describe the 
performances of missiles or drones in modern warfare. Remarkably, the source domain in turn 
makes an extensive use of medical analogies such as ‘surgical strikes’, a metaphor used in 
warfare strategy and communication during the First Gulf War. No matter whether you want 
to heal people or kill them, no matter whether your action is good or bad, the ultimate values 
are control and precision. 
 
The magic bullet in the context of crisis of pharmaceutical innovation 
 
The hype surrounding nanotechnology and the claims that it brings about a revolution in 
medicine and pharmacy are based on the awareness of the limitations of current trends in 
pharmaceutical research. The frantic quest for the miracle molecule that would cure all 
cancers following Richard Nixon’s launch of the ‘War on Cancer’ in 1971 ended in failure. It 
is now widely accepted that the ‘blockbuster model’ is inadequate. Cost soars and the rise of 
generic drugs are putting an increasing pressure on big pharmas as their amount of R&D time 
and expenditures rise while the output of new therapeutic molecules decreases (DiMasi et al., 
2003; Munos, 2009; Swinney and Anthony, 2011). Many products that are tested in clinical 
trials fail despite tremendous time investments —up to 15 years —and resource spendings. So 
hard is the ‘Valley of Death’ for candidate molecules before reaching the market that selective 
reporting of trials is a temptation for pharmaceutical companies (De Angelis et al., 2004; 
Goldacre, 2012).  
In the face of this crisis, genomics, genetic engineering, nanotechnology and synthetic 
biology are expected to reinvigorate a decaying business model (Crawford, 2004; Paul et al. 
2010). Both personalized medicine and targeted drug delivery attract big investments from the 
private and the public sectors concerned with the sustainability of the public health system 
(Downing 2009). They search for more ‘rational’ (based on molecular features) and more 
‘reasonable’ (more profit and increased efficacy) ways of designing pharmaceutical products 
through more individualized administration of drugs. While in personalized medicine better 
administration means better prescription,3 in drug targeting it translates as better delivery. 
Personalized medicine and target drug delivery are seen as complementary rather than 
competing strategies (Jain, 2005; Morris, 2012).4 By adjusting prescription and delivery to 
                                                 
3
 Because all individuals are not responding to the same drug, personalized medicine is looking for molecular 
signatures—so called ‘biomarkers’—that would allow to direct different categories of patients to more adapted 
therapies, possibly on the basis of early diagnoses (molecular biomarkers are anything that can be detected and 
used for measuring the probability of incidence of a disease, its progress, or its treatment’s effects: DNA or RNA 
single nucleotide polymorphism, protein, complex of proteins, or changes in protein expression).  
4
 Personalized medicine seeks to specify therapy by means of profiling and stratification: It sets up distinct 
categories of patients with regard to their probability of better responding to this or that therapy on the basis of 
tests determining the presence of a biomarker. It is to form categories of patients fitting with prescriptions and 
conversely to adjust prescriptions to categories of patients. Targeted drug delivery, by contrast, starts from a 
Authors-generated preprint | NanoEthics, 2014, vol. 8, n°1, pp. 1-17 | DOI 10.1007/s11569-013-0183-5 
http://link.springer.com/article/10.1007%2Fs11569-013-0183-5 
 5 
individual profiles, well-established medicines may be used to better effect (Chess, 1998). It 
is a key argument for stimulating public adhesion because it seems to overcome the 
disadvantages and defects of conventional therapeutics. Both sectors have raised intense 
mobilization over the past decade as a result of a remarkable convergence of interests between 
patients, science, politics and business. Patients and physicians want to avoid the damages 
caused by conventional chemotherapy and radiotherapy in the treatment of cancers. 
Pharmaceutical companies want to avoid the rising research costs for new therapeutic 
molecules, and public health services want to avoid the tremendous financial loss due to the 
inefficacy of a large proportion of medical prescriptions. Although big pharmaceutical 
companies are still hesitant to invest in this field5, they see targeted drug delivery as an 
opportunity to renew their patent portfolios6. On the business side, drug targeting is expected 
to cover 75% of the nanomedicine market (Wagner et al., 2006). Therefore hundreds of 
research laboratories across the globe are currently bringing together the resources from 
nanotechnology, advanced polymer and lipid chemistry, physics and molecular biology in 
order to find new ways of vectorizing drugs. Such is the pressure for introducing this new 
technique in cancer therapeutics that hundreds of candidate products are now in clinical trials. 
It is reported that 27 candidate products have already been approved by the US Food & Drug 
Administration in 2012 (Observatory NANO, 2012). Targeted drug delivery has become a 
target in itself justifying a warlike mobilization, reinforced by a rhetorical arsenal of 
‘therapeutic missile’, ‘smart bombs’, and the like. As the military metaphors inspire a 
convergence of efforts on a common target designated as the enemy, they are self-vindicating. 
In using them, nanotechnologists, physicians, and patients struggling against cancer may feel 
that they participate in a general mobilisation for an intrinsically good cause (Nerlich, 2012). 
 
The magic bullet and the two cultures of pharmacology 
 
The climate of crisis in pharmaceutical innovation may have intensified the use of warfare 
metaphors but the metaphors have been around in the twentieth century. Their success 
testifies to the triumph of the chemical approach to medicine, initiated by Paracelsus in the 
sixteenth century against the older Galenic tradition7. Paracelsus grounded his therapeutic 
approach on a theory of secrete correspondences or sympathies between each of the seven 
metals known in his time and the specific parts of the human body (Debus 1991; Debus 
1993). He assumed that disease was caused by external foreign agents acting as poisons on a 
specific area of the body. Diseases were viewed as localized physical things that the physician 
sought to eradicate from the body with the help of an appropriate chemical substance. By 
contrast, the Galenic tradition emphasized the role of fluids and viewed disease as the result 
of disturbance in the balance of fluids due to an excess of one of the four basic humours. The 
                                                                                                                                                        
given molecule and a given target (organ, tissue, cell, organelle or molecular receptor) and seeks the most fitting 
nanoscale formulation to carry the molecule to the target. 
5
 Currently, the innovation landscape of nanovectorization is mostly populated with small start-ups selling their 
patents to big pharmaceutical companies. (Observatory NANO 2010). They rely on venture capitals and business 
angels to bear the costs of preclinical development, scaling-up studies, upgrading to legal standards, and phase-I 
to mid-phase-II trials. Big pharmas cover only end-phase-II and phase III. They adopt a ‘wait-and-see’ strategy 
(te Kulve & Rip 2013: 4) and refuse to rush head down towards a disruptive technology unless it has 
pugnaciously proven its safety and efficiency (Couvreur 2010b).  
6
 It is expected that targeted drug delivery will provide pharmaceutical industry with new patents thanks to the 
nanoformulation of established molecules before the end period of their IP rights. It also allows patenting older 
medicines that so far could not enter the market (Bawa, 2008; te Kulve & Rip 2013: 3).   
7
 Here we take the two rival founding fathers as mythical figures. It matters little to us whether Galen and 
Paracelsus were really what their heirs have made of them. The master narrative built on the two heroes are still 
framing pharmacological culture. 
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role of the physician was to restore what we call today the body’s homeostasis by prescribing 
the opposite humour. While Galenic medicine dealt with the organism as a whole and a nexus 
of relations, Paracelsian therapeutics rests on the affinity of chemicals with specific tissues. 
The holistic concept of disease characteristic of the Galenic tradition has been overthrown by 
an ontological concept of disease as an ens morbi, a material and localized entity. 
The idea of eradicating disease with an appropriate molecule came out of advances in 
synthetic chemistry and stereochemistry at the turn of the twentieth century (Pillai et al., 
2008). Paul Ehrlich, in particular, paved the way to targeted medicine. As a ‘microbe hunter’, 
he was one of the first scientists to use staining techniques to detect particular cells. While 
studying the selective action of aniline dyes on biological tissues, he hypothesized that cells 
have specific receptors enabling them to take up specific molecules. Just as Emil Fischer had 
ventured the analogy between lock and key to explain how enzymes bind with specific 
substrates, Ehrlich used the hypothesis of chemical affinities—called today ‘mechanisms of 
molecular recognition’—to identify toxins with a selective therapeutic action on specific cells. 
He thus tested hundreds of dyes on mice in search for the unique dye that could target the 
large trypanosome responsible for sleeping sickness. In 1910, he obtained an effective drug 
against syphilis, Salvarsan. Based on the molecular recognition between toxin and tissue, his 
strategy inspired the image of ‘magic bullet’, chosen as the title for a 1940 biographical 
movie, Dr Ehrlich’s Magic Bullet (Fig.1).8  
 
 
 
Fig. 1. Dr Ehrlich’s Magic Bullet, 1940, original motion picture poster, © 1940 Warner Bros. 
  
                                                 
8
 Ehrlich wrote that “If we picture an organism as infected by a certain species of bacterium, it will obviously be 
easy to effect a cure if substances have been discovered which have an exclusive affinity for these bacteria and 
act deleteriously or lethally on these alone, while at the same time they possess no affinity for the normal 
constituents of the body and can therefore have the least harmful, or other effect on that body. Such substances 
would then be able to exert their full action exclusively on the parasite harboured within the organism and would 
represent, so to speak, magic bullets, which seek their target of their own accord” (Ehrlich [1906] 1960, p. viii). 
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So appealing was this popular image that it has been taken up by drug designers and 
gradually became a kind of ideal-type driving research efforts (Strebhardt and Ullrich, 2008). 
The ‘magic bullet’ model underlies many research strategies that came to prevail in twentieth-
century pharmaceutical industry. New techniques invented in the 1960s reinforced the 
Paracelsian concept of disease as a local target to shoot. When systems of controlled drug-
delivery came into use for a number of diseases (Hoffman, 2008), the ‘magic bullet’ became a 
fashionable motto. The metaphor almost turned into a real thing in the 1970s as 
pharmaceutical companies began producing monoclonal antibodies by cloning a unique 
parent cell having some specific action on tumours. It became even more prevalent with the 
proofs of concept of ‘microspheres’ (Kramer, 1974), ‘Nanokapsul’ (Kopf, 1975), and 
‘Nanopartikel’ (Kopf et al., 1976) that penetrate into specific cells for drug, gene or protein 
delivery, due to Peter Speiser and his team at ETH Zürich (Couvreur et al., 1977; Kopf et al., 
1977; Marty, 1977; Marty et al., 1978). The ‘magic bullet’ is now integrated in more complex 
systems aimed at materializing the ideal-type of targeted therapeutics. The expectation is to 
shift from the painstaking drug screening—testing lots of molecules on all possible targets—
to the direct design of the unique weapon adjusted to its target.  
The pharmaceutical arsenal enriched with such magic bullets is clearly an outcome of the 
Paracelsian tradition. To what extent does it mark the death of the Galenic approach to 
diseases? Could targeted drug delivery be alternatively viewed as a revenge of Galenics, as it 
has been suggested by Patrick Couvreur, a Belgian scientist who pioneered the field of 
targeted drug delivery? (Couvreur, 2009) Surely, drug delivery just like today’s Galenic 
pharmacology is concerned with the formulation and administration of drugs. 9 The delivered 
substance matters less than the mode of delivery. All efforts are thus aimed at designing new 
medicinal forms (Galenic forms) rather than new drugs. The goal is less to increase the 
efficiency of the therapeutic agent than to enhance the therapeutic index (the toxic vs. 
therapeutic dose ratio) by increasing the efficacy of delivery.  
Are we to assume that targeted drug delivery may be seen as a reconciliation of the two 
alternative conceptions of disease and therapeutics? To address this question, it is necessary to 
characterize the material practices of design.  
 
Engineering therapeutic devices 
 
Current research on targeted drug delivery differs in substantial ways from both traditions in 
that it turns therapeutics into engineering. Indeed, like all therapeutic traditions, targeted drug 
delivery is mainly concerned with maximizing the efficacy of treatment and reducing harm. 
As such, however, therapeutics is conceptualized as an engineering problem that can be 
anatomized in unit operations.  
The technique is divided up in three basic unit operations: loading, addressing, and 
releasing the active therapeutic molecule, each operation having specific design requirements. 
This sequence of operations could apply to the preparation of a missile, and the therapeutic 
action is conceived in terms similar to any ballistic problem.   
The first operation—loading (Fig. 2)—requires the design of a vehicle (capsule, sphere, 
micelle, dendrite, shell…) ‘to carry the drug in a controlled manner from the site of 
                                                 
9
 Significantly, twentieth century Galenics refers to the ‘formulation’ of drugs, i.e.: making tablets, suppositories, 
creams or syrups, according to a specific procedure called a ‘formula’ (a medicinal form suitable for 
administration). Galenics is often despised by modern pharmacology as being concerned with external form or 
packaging instead of active principles, as being technique or even marketing, not science—a rather unfair view, 
since it is Galenics that allows the transformation of a mere ‘drug’ into a proper ‘medicine’. Galenic pharmacy is 
indeed indispensable for the standardisation of doses and posology as well as for the stabilisation and 
conservation of active substances (Rasmussen, 2005). Galenics is the art of taming substances. 
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administration to its therapeutic target’ (Couvreur, Vauthier, 2006: 1417). Since the first 
capsules synthesized in the 1970s with polyacrylamide, polyalkylcyanoacrylate, albumin, or 
micelles, numerous candidate materials—polymers, liposomes, cyclodextrins and other 
nanoparticles—have been tested as drug vehicles.  
 
 
Fig. 2. Encapsulation of a drug in a liposome (S. Loeve, original picture). 
 
There are some specific requirements for the design of a nanocarrier: size (it must not be 
too big, not too small in order to selectively cross barriers); encapsulation rate (it must take up 
a reasonable amount of therapeutic molecules while polymerizing10); stability (it must resist 
bio-erosion); biocompatibility (solubility and avoidance of unwanted accumulation) and 
biodegradability once the capsule’s mission is completed. 
Addressing the drug by controlling the movements of the carrier along its trajectory is the 
core of the targeting strategy. Ballistic metaphors flourish to describe the battery of 
techniques that have been developed. Although ‘vectorization’ does not explicitly convey a 
military image, it connotes the trajectory of a mobile through a geometrical space, which is 
the key concept of ballistics. The frequent use of the arrow symbol in the iconography of 
nanovectors reminiscent of the Euclidian vectors used in classical physics reinforces the  
ballistic connotation. In addition, fighter aircrafts are often referred to as ‘vectors’ in the 
control rooms of military operations. In the case of functionalized nanocarriers with receptor-
specific ligands, the ballistic metaphor of the ‘missile’ or ‘vector’ is often supplemented with 
the cybernetic metaphor of the ‘homing device’ 11 , thereby converting the old ballistic 
metaphors into modern (informational) warfare and ‘smart’ weapons. To cap it all, theranostic 
nanoplatforms guided by ultrasounds or magnetic fields are designed as kinds of drones: their 
destructive payload can be remotely triggered while their localization can be tracked on a 
screen. Nanovectors rhyme with Terminators (i.e, robots programmed to kill and to never 
miss their target). The so-called ‘third-generation nanovectors’ (Couvreur and Vauthier 2006) 
                                                 
10
 The encapsulation rate is one of the major bottlenecks for the technique. Currently, most systems do not 
exceed a rate of 10% of active principles encapsulated on the total amount of nanoparticles synthesized, which 
limits both their cost-efficiency and therapeutic index. 
11
 Actually, Norbert Wiener’s conceptualization of feedback or retroaction originated in his warfare research on 
self-guided devices during World War II (Galison 1994).   
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are designed for ‘active targeting’ thanks to their ‘decoration’ with ‘molecular probes’ 
(antibodies or ligands) devised to recognise the target’s specific receptors (Fig.3). These 
specific ligands grafted on the carrier’s coating are often dubbed ‘homing devices’. They can 
also feature cell-penetrating peptides or intracellular adhesion molecules to facilitate the 
intracellular penetration of the vector (Hillaireau and Couvreur, 2009).  
 
 
 
Fig. 3. Three generations of nanovectors according to Couvreur and Vauthier (2006). (S. Loeve, original 
picture). 
 
In addition to chemical means of targeting, active targeting can also be obtained by using 
physical stimuli such as X-rays, infrared, ultrasounds, or magnetic field providing guidance 
(with magnetite embedded in the carrier). Embedded magnetite adds another interesting 
function to the drug-loaded carrier because it can be detected by Magnetic Resonance 
Imaging. In this case, the same nanodevice acts both as a therapeutic tool and an instrument of 
in vivo detection and imaging—thus combining therapeutics and diagnostics into one single 
operation, dubbed ‘theranostics’.12  The device is somewhat similar to a drone: It is remotely 
guided while its position is followed on a screen. Other detection and imaging compounds 
include contrast agents, antibodies emitting fluorescent light when binding with their target 
receptor, or DNA probes activating a fluorophore when hybridizing with their complementary 
strand (Tiwari et al. 2011). Nanoparticles with embedded iron oxide lining up in a chain and 
changing direction under the influence of a magnet provide the most suggestive image of a 
nanorobot. Florence Gazeau, from Université Paris-Diderot, explains: ‘The remote control by 
the application of forces works like a robot: It is the mechanical manipulation of a biological 
                                                 
12
 Originally coined to refer to a treatment platform combining a diagnostic test setup with a therapy based on 
the evolution of the test results (Warner, 2004), theranostic nanomedicine is now defined as ‘an integrated 
nanotherapeutic system which can diagnose, deliver targeted therapy and monitor the response to therapy’ 
(Sumer and Gao, 2008, p. 137). 
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object’ (Gazeau, 2011).13  
The third operation—the release of the drug on the targeted site—can be triggered either 
from inside by controlling the stability and degradation time-lapse of the capsule, or from 
outside by various stimuli-response devices. All the unique properties of the nanoscale can be 
exploited. For instance, pH-sensitive liposomes and nanoparticules such as chitosan will 
disassemble before a tumour in an acidic environment; or a carrier made of a thermo-sensitive 
polymer will become porous by application of hyperthermia on the target and will then 
release its load; a polymer-coated gold nanoparticle will do the same when irradiated under 
near-infrared pulsed light, which penetrates deeply into the tissue and causes gold liquefaction 
(Shakeri-Zadehl et al. 2010, Choi et al. 2011); an iron nanoparticle will overheat and cause 
cancer cell’s necrosis when subjected to a magnetic field. In the latter case the nanoparticle 
becomes the drug: Drug and device merge.14 
Each unit operation—loading, addressing, releasing—involved in targeted drug delivery is 
assigned to a specific device. The combination of these devices in a nanoparticle is often 
called a nanomedicine ‘platform’ because of the device’s multi-tasking performance: imaging 
(optical, ultrasound or magnetic resonance detection), targeting agents (peptides, 
antibodies…), therapeutic tools (chemotherapy, hyperthermia…), and stimuli-responsive 
agents that activate those functions (Fig. 4). 
 
 
 
Fig. 4. A nanomedicine platform: an assembly of specific functions (S. Loeve, original picture). 
                                                 
13
 Here, ‘robot’ clearly means an enslaved machine-tool, not an independent automaton. This is not surprising, 
since, as Nerlich argues (2005; 2008), the images of nanobots cleaning fats in blood vessels are recycling the 
older visual archetypes of shrunk humans travelling through the body, as shown in the movie The Fantastic 
Voyage. Nanomedicine’s imaginary has replaced shrunk surgeons and their tools with miniaturized robots. In 
turn, the focus has shifted ‘from the “extraordinary” (voyages) to the “ordinary” (medicine), thereby contributing 
to the normalisation of nanomedicine and its integration into normal biomilitaristic medical discourse’ (Nerlich, 
2012). The metaphor of the nanorobot has had to be ‘militarized’ to move from pure science fiction to something 
real, serious, and valued by our society. 
14
 A striking example of fusion between drug and device is the NanoXray™ developed by the French start-up 
Nanobiotix (http://www.youtube.com/watch?v=kxSX6YJTS2I), in which the nanoparticles amplify the physical 
mode of action of radiotherapy. NanoXray™ is like a nanoscale extension of the radiotherapy setup internalized 
in the patient’s body to relay and locally amplify its effect. This conflation is also visible in the normative 
framework of regulation under which the development of NanoXray™ is placed: under the category ‘drug’ by 
the US FDA and under the category ‘medical devices’ by the French AFSSAPS. This later regime of regulation 
would, if not accelerate, at least facilitate NanoXray™’s entrance in the market by bypassing the ever-expanding 
‘valley of death’ of pharmaceutical development. As a venture capitalist investing in the start-up put it on one of 
the Nanobiotix’s site podcasts, ‘I believe we are getting a biotech care company potential with a medical device 
time-to-market’ (http://www.nanobiotix.com/about-us/). 
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The resulting system is like a ‘mille-feuilles’ of disciplines comprising of various layers:  
synthetic chemistry, physics, biochemistry or molecular biology (figure 5). Like most nano-
engineering projects the design of nanocapsules requires the convergence of various 
disciplines at the nanoscale. To a certain extent the nanocarriers are crafted like ‘materials by 
design’, they are then functionalized for performing specific tasks. 
 
 
 
Fig. 5.  Layered structure of a multifunctional nanoparticles: A ‘mille-feuilles’ of disciplines. (S. Loeve, original 
picture). 
 
It should be clear by now that the resulting approach to therapeutics belongs neither to the 
Galenic culture of pharmacology nor to its Paracelsian rival. In opposition to the Paracelsian 
approach, the chemical agent is by no means the unique active principle of the medicine. It is 
part of a larger technological system combining various functions that all cooperate to the 
therapeutic action. Conversely, the Galenic formulation becomes so functionalized at the 
nanoscale that it is no longer possible to draw a clear boundary between the excipients and the 
active principle (Loeve and Normand, 2011). The formulation is an integral part of the 
therapeutic system.15 Targeted drug delivery systems do not fit in the traditional categories of 
pharmacological culture and knowledge. They instantiate a technoscientific approach 
dominated by an abstract engineer’s view16. Even the performances that are expected from 
them are formulated in the language of technology assessment (cost/benefit analysis). Each of 
the functions added to the nanoplatform should increase the ratio of benefits versus costs and 
be assessed under this model (Cheng et al. 2012).  
 
 
                                                 
15
 The nanocarriers obtained by ‘squalenization’ by Couvreur and his team instantiates the identification of the 
drug with its Galenic formulation. Squalene, a biological organic compound, can chemically bind with the 
anticancer drug gemcitabin, thus forming a new molecular entity, gemcitabine-squalene, which in turn self-
assembles into nanoparticles in water (Phili et al. 2010). 
16
 On the difference between abstract and concrete engineering views in nanotechnology see Bensaude-Vincent 
and Guchet (2007, pp. 79-82).  
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From a model of efficiency to therapeutic efficacy 
 
The missile metaphor is attractive because of the translation of a therapeutic project into an 
engineering problem with clear end (cure cancer) and means (nanocarriers for the transport 
and stimuli for the release of the medicine). However, is the ballistic metaphor sufficient, is it 
even necessary? What kind of model is required to combine technological efficiency with 
therapeutic efficacy?17  
First of all, if the warfare metaphor is to be maintained, it requires at least more than 
performing the sequence of unit operations: loading, addressing, releasing. To successfully 
deliver the right dose in the right place at the right time in the complex environment of a 
living organism requires at least ‘smart weapons’ with  multifunctional parts. Consider the 
first unit, the capsule. It has to be designed both as a vehicle and as a container for 
transporting the active principle. While the nano-size facilitates the circulation through the 
blood vessels and allows intravenous injections (usually the most dangerous drug 
administration route for the risk of embolism), for containing the optimal dose of active 
principle, the nanocapsule presents the inconvenience of a low volume for drug loading. 
Designing the capsule implies a trade-off between size and dosing. For a successful 
therapeutics, the designer has to find out the optimal trade-offs afforded by the nanoscale, 
with regard to the kind of effect s/he chooses to prioritize.  
In addition, the capsule does not only carry a ‘payload’, it also protects the biological 
milieus from the virulence of the active principle. Targeted drug delivery really took off when 
doxorubicin has been encapsulated in biodegradable polyalkylcyanoacrylate nanoparticles 
(Couvreur et al., 1982), lessening the drug’s notorious and often prohibitive cardiac toxicity. 
The container secures the containment of a dangerous material. Its protection is also crucial 
for expanding the spectrum of potential drugs to biological substances. So far peptides, 
proteins, nucleic acids have been considered as undeliverable because they are rapidly cleared 
and degraded in the biological milieu. The still uncertain future of gene therapy will thus 
depend on the ability to protect the fragile drug through its journey. Whether the therapeutic 
principle is a highly toxic substance that needs to be isolated from the vulnerable milieu or a 
fragile degradable biological material that needs a protective container, in both cases, the 
carrier affords care. 
Second, achieving a successful therapy is not simply a matter of guiding a projectile 
toward a target with the highest precision and optimal trajectory. The designer of the ‘smart 
bomb’ has to ensure the stability of the vehicle in the messy biological milieu for increasing 
its residence time in blood vessels. This challenge requires astute tricks to deal with obstacles 
occurring at each step. The first obstacle is the opsonisation of the carrier (the marking of a 
foreign body alerting the defences of the host organism that this exogenous element has to be 
cleared out from the blood vessels). How to negotiate with this self-defence of the host 
organism? To face this obstacle the ‘magic bullet’ had to be disguised or coated. The so-
called ‘second-generation nanovectors’ (Couvreur and Vauthier 2006) are grafted with a sort 
of hair on the surface of their capsule to make them invisible to the macrophages along their 
trajectory. Made of a polymer—most often polyethylene glycol (PEG), because it is FDA 
approved, cheap and biodegradable—the coating creates a cloud of hydrophilic chains, which 
repels for a time the plasma proteins that mark the non-self. This process named pegylation 
protects the carrier from disintegration by the immune system, thus enabling its circulation in 
                                                 
17
 Efficacy is generally defined as the ability to bring about a desired effect, whereas efficiency measures the 
ratio of beneficial output (e.g.: useful fork, economic profit) versus (the amount of means/resources) involved 
(time, energy, effort, costs…). Therapeutic efficacy is the main concern in the development process (where it 
becomes the most important criterion). 
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the blood for a much longer period of time. The pegylated particles have a circulating half-life 
of 45 hours versus a few hours for conventional liposomes.  
It is thus clear that the missile metaphor is over-simplistic and not sufficient to achieve 
therapeutic efficacy. More importantly, this metaphor conveys the misleading image of a kind 
of navigation system. Unlike a homing missile, the nanovector is not heading straight from 
the injection site to the target.18 It has a random and hazardous journey through the blood 
vessels until it meets its target and binds to it.19  
Finally, the image of a weapon hitting a target is not even appropriate to describe the 
release of the drug. One major challenge is that along its journey through the blood vessel, the 
decorated carrier is modified by the milieu and even redecorated by it, for instance by 
dragging a variety of proteins forming what toxicologists name the ‘protein corona’. The 
proteins in the serum form a protective shield, which alters the targeting capabilities of the 
device (Gaspar, 2013). What the tumour cells ‘sees’ is not the expected keys that fit in their 
locks. They ‘see’ a different and unreadable message (Gazeau, 2011). Whereas an 
unambiguous lock-and-key response is expected from the target, the target actually affords a 
unique viewpoint on the nanoparticles, opening unexpected perspectives over unforeseen 
interactions.  
Thus the target is by no means a passive site of impact. Rather it is a new milieu 
reconfiguring the particle’s identity. One major challenge for the success of drug delivery 
devices is therefore to continuously pay attention to the interactions between the technological 
device and the milieu. 
The description of the nanoplatform as an assemblage of independent functionalities that 
can be activated by internal or external stimuli is somewhat misleading. It does not take into 
account the synergistic or antagonistic effects between the artifact and the milieu, which may 
alter the devices’ functions and effects. The image of a carrier moving straight to hit a specific 
target is only an abstract model that may be appropriate to conduct laboratory experiments. 
While in vitro tests are indispensable for obvious epistemic and ethical reasons, they tend to 
generate illusions of control and efficiency. They may become counter-productive if they 
conceal the problems posed by the complex and stochastic behaviour of the biological milieu. 
It is thus clear that a strict Paracelsian chemical approach to drug delivery is doomed to fail in 
nanomedicine.  
To improve the current strategies of drug delivery with nanocapsules, is it possible to 
bridge the gap between in vitro and in vivo performances by integrating the milieu as a third 
player in the game? While the problem is generally framed in terms of targeting the drug-
loaded nanovehicle with increased control precision, more efficient and more robust devices 
relying on the actions and reactions of the cells are designed.  Similar to those were the so-
called ‘first-generation’ and ‘second-generation’ nanovectors. For instance, the ‘second-
generation’ nanovectors capitalize on a stratagem developed by the tumour to capture a part 
of the blood flow. Whereas in healthy blood vessels endothelial cells are bound together by 
tight junctions, preventing any large particle in the blood from leaking out, in tumours or 
inflamed tissues, blood vessels do not have the same sealing ability and are consequently 
more permeable. This increased permeability known as Enhanced Permeability and Retention 
                                                 
18
 To be sure, military missiles sometimes release munitions without homing devices, at random, in the hope 
that enemy targets will be affected by statistics. But they don’t have the glamour of surgical strikes. 
19
 Even when the drug carrier is equipped with specific antibodies, peptides or ligands, these so-called ‘homing 
devices’ do not point only to a target receptor, but also sometimes to a relay receptor enabling the nanovector to 
cross a biological barrier. For instance, when decorated with the specific antibody of the transferrin receptor, 
chitosan nanospheres can cross the blood-brain barrier for delivering biologically peptides to the brain (Karatas 
et al., 2009). In this case, a temporary alliance is contracted with a smuggler afforded by a particular biological 
milieu. 
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effect (EPR) 20 of the tumour capillaries allows liposomes or nanoparticles to slowly permeate 
the tumour sites (Fig. 6). This ‘non-specific targeting’ (Fig.3) enables pegylated liposomes to 
reach tumours sites to deliver drugs while making chemotherapeutic drugs less toxic for 
healthy tissues. The doxorubicin-loaded liposomes Doxil® with their size of about 100nm 
allow administrating a higher dose of doxorubicin while providing the patients with a better 
quality of life (no more nausea, vomiting or hair loss), although new side effects are also 
experienced21. Doxil® totals almost $600 million in annual sales around the world and will 
soon lose its patent protection. 
 
 
 
Fig. 6. Addressing tumour tissue through Enhanced Permeability and Retention effect. (S. Loeve, original 
picture). 
 
New strategies for drug delivery are being envisioned that take into account the complex 
and dynamic nature of the biological milieu. In particular the modifications induced by the 
pathology and the treatment in the target at different space and time scales have to be 
systematically investigated. The tumor microenvironment is characterized by a high structural 
heterogeneity, multicellular composition, dense extracellular matrix, non-uniform leaky 
vasculature, continuously evolving interstitial pressure and solid stress, hypoxia and 
involvement of immune cells (Jain and Stylianopoulos 2010; Perrault et al., 2009). Multistep 
strategies are being envisioned including a first step to prepare the milieu (normalization of 
tumor vasculature or of the tumor matrix) and a second step to facilitate drug delivery to the 
cellular or intracellular target (Wong et al., 2011; Chauhan et al., 2012; Sano et al., 2013). 
Designing nanoparticles that respond to properties of the tumor microenvironment (for 
                                                 
20
 Enhanced Permeability and Retention is the effect of inflammation, which induces the arrival of macrophages 
and the release of cytokines increasing the permeability of vessels. 
21
 This is the case of the palmar-plantar erythrodysesthesia or ‘hand-foot syndrome’. Hands and feet are usually 
subjected to mechanical pressure and friction, which causes instantaneous dilatation of the endothelial tissue of 
blood vessels which, similarly to the EPR effect. Yet this allows the nanocarriers to locally cross the endothelial 
wall of healthy tissues. The areas affected become red, dry, peel, numb or painful, with possible necrosis. This 
unwanted leakage of the nanocarrier can be attenuated by modifying some everyday activities (avoiding wearing 
tight clothes, using tools, jogging, taking hot showers or being exposed to strong sunlight). But for very sensitive 
patients such an adverse effect unfortunately limits the maximal safe Doxil® dose that can be administrated as 
compared with doxorubicin in the same treatment regime. 
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example low pH and partial oxygen pressure) is a major trend in the field of cardiovascular 
diseases. Targeted drug delivery could also be ‘pathology-inspired’, that is, achieved through 
endogenous disease-specific mechanical stimuli.22 Here again the interactions of nanocarriers 
with the milieu, and more specifically with the diseased area, triggers opportunities of 
therapeutic activation. Such stratagems engaging with the milieu as a partner promise to be 
more robust and widely applicable than the simple molecular recognition initiated with the 
model of magic bullet. ‘Intelligent design’ (Couvreur and Vauthier, 2006) of drug delivery 
could be based on a better understanding of interaction mechanisms between the biological 
milieu and foreign bodies so as to benefit from them.   
The efficiency and efficacy of the military strategy of targeting and shooting are thus 
questionable. Even when it is extended beyond the realm of ballistics to encompass smart and 
fine-tuned devices performing various functions, the missile metaphor is not fully adequate. 
Twelve years of intensive research did not bring about the promised results. The expected 
economic benefits are so disappointing that some experts recommend reconsidering the entire 
technology in close interactions with users and regulatory agencies (Te Kulve and Rip, 2012).  
It is now clear that the exclusive focus on the nanoparticle (the vehicle) conceals many 
complex phenomena associated with transport through a living body (Kwon et al., 2012). It 
reduces the spectrum of possibilities by excluding other potential perspectives. While the 
image of a missile provides insights, it also generates new forms of ignorance precisely 
because of its evident simplicity. In particular the offensive rhetoric undermines a subtle fine-
tuning between a variety of mechanisms of protection or even of care. First, the biological 
tissues are protected from the drug’s toxicity thanks to the container, which is in turn 
protected from the body’s defences by the coating. As a matter of care, targeted drug delivery 
requires a sense of tact and diplomacy. The so-called ‘missile’ has to be also a ‘secret agent’ 
in order to infiltrate into a series of biological milieus and manipulate the interactions between 
various protagonists. Like the Trojan horse, the nanocapsules conceal their operation by 
adopting the codes of the infiltrated milieu. The so-called ‘missile’ has to negotiate access 
like a good diplomat. Instead of subjecting all obstacles along its path, it has to establish 
temporary alliances with various smugglers. Nanovectors require the tricks of a wizard and 
the special talent of kaïros. This persona of Ancient Greek mythology, the son of Athena and 
grand-son of Zeus and Metis, is good at seizing opportunities. He epitomizes the art of 
making decision in the right place and at the right moment. This art consists in seizing what 
the situation affords for performing the next step in an action.  
 
Towards an oïkological approach 
 
Since the missile metaphor is neither sufficient nor necessary to account for all the spectrum 
of astute stratagems required to secure therapeutic efficacy, it seems relevant to open the 
register of linguistic practices to alternative metaphors. It is especially important because, as 
Bjorn Hofmann convincingly argued (2001), technology plays a leading role in framing 
medical knowledge. It contributes to shape our concept of disease, our vision of medical 
intervention on the human body and, last but not least, our vision of the body. The ballistic 
metaphors rely on an abstract view of the body as a blank geometrical space through which a 
vector is moving towards a target. By contrast, the emphasis on the interaction with the 
biological milieu conveys the view of the body as a complex and heterogeneous environment. 
It consequently brings to mind a quite different metaphoric framework.  
We suggest that drug delivery research could be advantageously framed in terms of 
domestic economy or ‘oïkology’ (from oïkos, ‘house’, the common root for both ecology and 
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 For this purpose, lentil-shaped liposomes were designed to release their content only under the high shear 
stress found in constricted blood vessels (Korin et al.; 2012 Holme et al., 2012). 
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economy). The concern with the management of doses and transportation, which prevails in 
the still fashionable military metaphors, would be supplemented by an art du ménagement 
(care). From this perspective, the designer would have to take care of the interactions between 
technological devices and the milieu where they operate. In the oïkological model, the human 
body is conceived as an oikos populated with a variety of habitants. It is a crowded and 
uneven terrain, a landscape of ecological niches. In the military framework, drug delivery is a 
strategic game opposing two players—the drug and the target—, whereas in the oïkological 
framework the game involves a variety of players capable of assuming various roles. Each of 
them requires care, protection and tact for the process to work. Their local interactions have to 
be orchestrated from place to place as the drug pursues its journey inside the body. In the 
ballistic vision, the therapeutic devices are positioned against the barriers that stand between 
the healthy organism and the pathogen target. In the oïkological vision, recovering health is to 
inhabit and tame the sick body, which is actually a plausible view of cancer (Merlo et al., 
2006; Boenink, 2009; Gatemby, 2009; Gatemby et al., 2009a; 2009b; Caroll, 2011).  
To develop an alternative oïkological metaphoric framework we have to clarify the mode 
of existence of nanomedical devices for targeted therapy. For this purpose, the conceptual 
distinction between dispositions and affordances may be helpful. It is often claimed that 
nanotechnology enables to control and monitor the delivery process (Park, 2007, Gabizon, 
2001). The objects designed for drug targeting are usually named ‘nano-devices’—a very well 
chosen term, because ‘devices’ (in French ‘dispositifs’) precisely can activate dispositions. To 
put it in more philosophical terms, nanoplatforms rely on dispositional properties when they 
are designed as missiles.23  In the case of nanoplatforms, the dispositions are the unique 
physicochemical properties of the nano-scale that can be actualized in a specific ‘dispositif’. 
Targeted drug delivery systems are ‘devices’ precisely because they activate dispositions. By 
contrast the term ‘affordance’ refers to the intrinsic capability of an object as well as to the 
gift or the service that the said object is able to deliver to its user (for instance thick ice 
affords skating).24 Affordances combine generic material dispositions and specific intentions 
and purposes. Whereas a disposition is a latent property inherent to a substance or based on 
the laws of nature, affordance is relational and definitely not substantial. Unlike dispositions, 
affordances are not latent potentials waiting for being activated; they do not pre-exist their 
actualization. Affordances are created within and by the coupling of an agent and a material 
system; they are rendered possible by this encounter. Affordances thus blur the 
potential/actual dichotomy, as well as the subject/object divide. Affordances are objective 
instances because they are offered by the environment and subjective because the offer is 
generated with regard to a perceptive agent. Affordances are hybrid entities—part constructs, 
part nature—whose causal powers cannot be disentangled.  
For instance, in today research programs on drug delivery, the process of opsonisation of 
the carrier is treated as an obstacle to be overcome, whereas in an ‘oïkologic’ framework, it 
would be treated as an affordance of the milieu. All the responses of the biological milieu to 
the introduction of a nanocapsule could serve as models of design. As pointed out by Richard 
Jones, nanotechnology could learn a lot from nature by investigating in vivo molecular 
                                                 
23
 To attribute a dispositional property to a thing amounts to saying that if certain conditions are obtained, then 
that thing will behave in a specific manner or bring about a specific effect. For instance ‘a negatively charged 
particle is one of which it is true that, if brought into proximity to another negatively charged particle, it will 
experience a force of repulsion’ (Harré 2001, p. 97). 
24
 In Gibson’s ecological theory of perception, affordances are the possibilities of action that are offered to an 
agent by an environment (Gibson, 1979). The concept has also been taken over in design theory, to express how 
objects invite and constrain their users by offering ‘cues for action’ (Norman, 1990; DiMaggio, 1997). It has 
recently been used by Rom Harré to develop a pragmatic account of scientific experimentation which consists of 
‘apparatuses/world complexes’ affordances (Harré, 2003). Apparatuses/world complexes afford things, 
processes and activities that cannot be constituted nor sustained independently from technical projects.  
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processes and try to capitalize on its findings—a major feature of what Jones dubs ‘soft 
engineering’: ‘The advantage of soft engineering is that it does not treat the special features of 
the nanoworld as problems to be overcome, instead it exploits them and indeed relies on them 
to work at all’ (Jones, 2004, p. 127).  
Changing obstacles into positive principles of work is exactly what the French 
philosopher Gilbert Simondon recommended for the design of ‘concrete’ machines as 
opposed to ‘abstract’ ones (Simondon, 1958). For Simondon, a ‘concrete engineer’ is one 
who pays attention to, and takes advantage of, the environment affordances. Unlike the 
abstract engineer, a concrete engineer does not aim to improve the machine’s efficiency first, 
to introduce it ultimately into its work environment. But instead, by imagining the machine in 
its environment and ‘playing the milieu’, the concrete engineer anticipates the effects of its 
operational effects on the environment, and then tries to integrate them into the machine’s 
working principles. A concrete nanomachine would work precisely because of—and not 
despite—its association with its environment, which becomes the machine’s ‘associated 
milieu’ and not an external parameter that engineers have to take into account after designing 
artefacts. Simondon’s ‘associated milieu’ is not something to which a standard, ready-made 
machine will have to be adjusted. It is an intrinsic aspect of the design of the machine. It 
means that each ingredient of the complex system is envisaged as a relational entity defined 
by its interactions with the environment rather than a physicochemical entity with a stable 
identity (table 1).  
 
Table 1 : Summary of the contrasts between the two metaphorical frameworks 
 
Representations  of 
 
Warfare Model  
 
Oïkological model 
 
 
Body 
Field of operations visualized on a 
radar screen. A passive, amorphous 
transparent and homogeneous 
space to go through to reach a 
target  
Multiple ecological niches 
interrelated by various modes of 
containement and interaction (e.g. 
selective membrane). An opaque, 
uneven and over-crowded milieu  
 
Disease 
 
 
A local entity to be eradicated 
 
A relational singularity to be tamed 
 
Health 
 
State of well-being resulting from 
the absence, or the destruction, of 
disease  
 
Inhabiting the body again. 
Learning process of adaptation to 
the new condition created by the 
disease (no return to the biological 
innocence)  
 
Therapeutic device 
Missile targeting a pathogenic 
entity 
 
Diplomat negotiating a 
compromise while taking care of 
her homeland 
 
Therapeutic act 
 
Strategic game between two actors: 
the drug and the target 
‘Art du ménagement’. Tactic game 
involving multiple actors to be 
interrelated and cared for at each 
step of the drug’s journey through 
the body 
Nano-object 
Transparent functionalized entity 
under control because it is the 
result of human design and 
engineering 
Relational entity defined by its 
interactions (e.g. protein corona)  
 
Conclusion 
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Brigitte Nerlich has suggested that Gibson’s notion of affordance could help conceptualize 
metaphors themselves in ecological terms. ‘An ecological theory of metaphor would study the 
“structural coupling” between a metaphor and the environment (…). Over and above its 
intrinsic semantics [the metaphor] therefore has a “pragmatic”, dynamic, action-oriented face’ 
(Nerlich, 2003, p. 136). If we assume, with Nerlich, that metaphors do have affordances, 
depending on their environment or ‘niches’, then we have to have to acknowledge the ‘magic 
affordances’ of the ‘magic bullet’ and the ‘therapeutic missile’.  
First, in the current context of crisis in pharmaceutical industry the missile metaphor 
affords public confidence. The underlying values of control and precision are more socially 
acceptable than the view of a nanovectors seizing opportunities in the course of a random 
journey through the body. Missiles and nanorobots are more reassuring for patients and more 
convincing for investors and industrial companies.  
Second, the image of a smart vector penetrating into a passive cell is clearly bound up 
with masculinity and reflects the gender bias that Fox Keller noticed in the accounts of 
molecular biology (1992). The preference for accounts relying on mechanisms of a stunning 
simplicity over others emphasizing complexity is a marked distinction of biotechnology and 
nanotechnology and can be related to the prevailing male vision of how the body works.  
Third, the over-emphasis on the dispositions of nanoparticles is also important for 
patenting purposes. Despite significant extensions over the past decade, the patent system still 
relies on claims of invention, and thus on artefacts. Since drug delivery research is mainly 
patent-oriented, it must avoid putting the emphasis on processes already performed by nature. 
Hence the idea that drug delivery research in comparison with other fields of nanotechnology 
only contains a small proportion of biomimetic stances—mostly limited to the ‘Trojan horse’ 
stratagems exemplified by viruses and phage.  
Despite its advantages, the missile metaphor does not do full justice to the complexity of 
the issue. Addressing drugs to a specific site and releasing the right dose in the right place at 
the right moment in the complex environment of a living body requires more than a magic 
bullet. In addition to the various disciplines that converge in all engineering project, 
nanomedicine requires the engagement of the biological milieu as a partner. Therefore, the 
Paracelsian model underlying the ballistic metaphor which may be adequate for in vitro 
demonstrations of efficiency must be completed by a genuine Galenic model of a complex 
and responsive milieu. The metaphor of the magic bullet has a limited heuristic power and 
brings about disappointing results. Ballistic is not the relevant technological model because it 
provides a distorted and biased view of the operations to be performed by nanomedical 
devices. Since they have to negotiate with the biological milieu and take advantage of what it 
affords by turning obstacles into facilitators, an alternative metaphoric framework is needed. 
It thus comes as no surprise that a number of recent research trends in targeted drug delivery 
focus increasingly on the milieu thus exploring the potentials of the ‘oïkological’ approach. 
(Loeve et al. 2013)  
 Although the broad question of the definition of nanoparticles remains far beyond the 
scope of this paper, it is not extravagant to suggest that the oïkological metaphor could be 
extended to other fields of nanotechnology, where it would afford new perspectives. If the 
relations between nanoparticles and their environment were no longer treated as side effects 
and rather as integral parts of their definition and characterization, research priorities could be 
dramatically changed. In today nano-initiatives nanotoxicological studies of interactions 
between nanoparticles and biological tissues or interactions with the environment are often 
viewed as a necessary detour for the safe and successful mass diffusion of nanotechnological 
products whereas they could become the hard core of the research field. This is just a tentative 
scenario of what might happen if nanoresearch were to focus on the interactions of nano-
objects with their environment. 
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